260 related articles for article (PubMed ID: 23760812)
41. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
42. Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
Jost LM; Gschwind HP; Jalava T; Wang Y; Guenther C; Souppart C; Rottmann A; Denner K; Waldmeier F; Gross G; Masson E; Laurent D
Drug Metab Dispos; 2006 Nov; 34(11):1817-28. PubMed ID: 16882767
[TBL] [Abstract][Full Text] [Related]
43. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
44. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
[TBL] [Abstract][Full Text] [Related]
45. Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat.
Mountfield RJ; Kiehr B; John BA
Drug Metab Dispos; 2000 May; 28(5):503-13. PubMed ID: 10772628
[TBL] [Abstract][Full Text] [Related]
46. Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro.
Zollinger M; Waldmeier F; Hartmann S; Zenke G; Zimmerlin AG; Glaenzel U; Baldeck JP; Schweitzer A; Berthier S; Moenius T; Grassberger MA
Drug Metab Dispos; 2006 May; 34(5):765-74. PubMed ID: 16467136
[TBL] [Abstract][Full Text] [Related]
47. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
Ruiz-Garcia A; Masters JC; Mendes da Costa L; LaBadie RR; Liang Y; Ni G; Ellery CA; Boutros T; Goldberg Z; Bello CL
J Clin Pharmacol; 2016 Feb; 56(2):223-30. PubMed ID: 26179237
[TBL] [Abstract][Full Text] [Related]
48. Metabolism and pharmacokinetics of indacaterol in humans.
Kagan M; Dain J; Peng L; Reynolds C
Drug Metab Dispos; 2012 Sep; 40(9):1712-22. PubMed ID: 22648561
[TBL] [Abstract][Full Text] [Related]
49. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
Ericsson H; Hamrén B; Bergstrand S; Elebring M; Fryklund L; Heijer M; Ohman KP
Drug Metab Dispos; 2004 Sep; 32(9):923-9. PubMed ID: 15319332
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.
Bathala MS; Masumoto H; Oguma T; He L; Lowrie C; Mendell J
Drug Metab Dispos; 2012 Dec; 40(12):2250-5. PubMed ID: 22936313
[TBL] [Abstract][Full Text] [Related]
52. Disposition of [1'-(14)C]stavudine after oral administration to humans.
Zhou L; Kaul S; Liu-Kreyche P; Tran SB; Espina RR; Warrack BM; Roongta VA; Iyer RA
Drug Metab Dispos; 2010 Apr; 38(4):655-66. PubMed ID: 20053818
[TBL] [Abstract][Full Text] [Related]
53. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Hill SJ; Giles PB; Phillips PJ; Lenz E
Clin Ther; 2003 Nov; 25(11):2822-35. PubMed ID: 14693307
[TBL] [Abstract][Full Text] [Related]
54. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
[TBL] [Abstract][Full Text] [Related]
55. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E
Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT).
Chiu JW; Chan K; Chen EX; Siu LL; Abdul Razak AR
Invest New Drugs; 2015 Aug; 33(4):895-900. PubMed ID: 25937431
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics, Disposition, and Biotransformation of [
Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
[TBL] [Abstract][Full Text] [Related]
58. Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation.
Bershas DA; Ouellet D; Mamaril-Fishman DB; Nebot N; Carson SW; Blackman SC; Morrison RA; Adams JL; Jurusik KE; Knecht DM; Gorycki PD; Richards-Peterson LE
Drug Metab Dispos; 2013 Dec; 41(12):2215-24. PubMed ID: 24097902
[TBL] [Abstract][Full Text] [Related]
59. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
Ling J; Johnson KA; Miao Z; Rakhit A; Pantze MP; Hamilton M; Lum BL; Prakash C
Drug Metab Dispos; 2006 Mar; 34(3):420-6. PubMed ID: 16381666
[TBL] [Abstract][Full Text] [Related]
60. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
